4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Iron Deficiency Anemia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 239 ongoing clinical trials involving Iron Deficiency Anemia
Of the 239 trials,80 trials are in Phase III
Furthermore, 71 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Iron Deficiency Anemia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Iron Deficiency Anemia, a Hematological disorder. The largest number of ongoing clinical trials for Iron Deficiency Anemia is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions engaged in Iron Deficiency Anemia-related drug trials.

Postgraduate Institute of Medical Education and Research: The leading ongoing Iron Deficiency Anemia related clinical trial sponsor

Postgraduate Institute of Medical Education and Research is the top sponsor for Iron Deficiency Anemia-related ongoing clinical trials.

Shield Therapeutics Plc, Viatris Inc, Nippon Shinyaku Co Ltd, University of Texas Medical Branch at Galveston, and Assiut University are among other notable clinical trial sponsors involved in Iron Deficiency Anemia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Iron Deficiency Anemia

Ferric carboxymaltose (Ferinject, Injectafer, Renegy), Iron sucrose (Venofer, Venoferrum, Noripurum), and Ferric citrate (Auryxia, Riona, Zerenex, Fexeric) are among the key marketed drugs involving Iron Deficiency Anemia.

Ferric carboxymaltose (Ferinject, Injectafer, Renegy) is an iron replacement product. It functions via the Iron Replacement mechanism of action. It is formulated as a solution for the intravenous route of administration. Ferric carboxymaltose is indicated for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. It is under development for the treatment of restless legs syndrome, iron deficiency anemia, chemotherapy-induced anemia, heart failure with iron deficiency, and reduced ejection fraction. Ferric carboxymaltose was first approved in 2007 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by American Regent Inc.

Iron sucrose (Venofer, Venoferrum, Noripurum) is a polynuclear iron (III) Hyrdroxide complex in sucrose. It functions via the Iron Replacement mechanism of action. It is formulated in the form of an injectable solution for intravenous administration and a solution for oral administration. It is used in the treatment of iron deficiency anemia in patients with non-dialysis dependent-chronic kidney disease (NDD-CKD) who receive erythropoietin, non-dialysis dependent-chronic kidney disease (NDD-CKD) who are not receiving erythropoietin, hemodialysis dependent-chronic kidney disease (HDD-CKD) receiving erythropoietin, peritoneal dialysis dependent-chronic kidney disease (PDD-CKD) receiving erythropoietin. Iron sucrose was first approved in 1949 and is marketed globally including the US, the UK, Australia, France, Germany, and China, by American Regent Inc.